Imcivree (Setmelanotide)

Setmelanotide is a selective agonist of the melanocortin‑4 receptor (MC4R) located in the hypothalamus. Activation of MC4R enhances satiety signals and increases basal energy expenditure, which together lower food intake and support weight reduction in patients whose genetic defects impair normal MC4R signaling.

The dose of Imcivree is individualized by the prescribing clinician based on the patient’s genetic diagnosis, body weight, and response to therapy. The medication is supplied as a prefilled pen delivering 0.5 mg per subcutaneous injection, and the prescriber determines the appropriate dosing schedule and titration plan.

Safety data for Imcivree during pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Imcivree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details—including cold‑chain handling if needed—and assist with import documentation.

Unlike conventional anti‑obesity drugs that act broadly on appetite or metabolism, Imcivree specifically targets the MC4R pathway and is approved only for genetically defined forms of obesity. This precision makes it effective where other agents have limited impact, but it also restricts its use to patients with confirmed MC4R‑related genetic defects.

Imcivree must be stored refrigerated between 2 °C and 8 °C. Keep the prefilled pen in its original packaging, protect it from light, and avoid freezing or shaking. If the product is inadvertently exposed to temperatures outside this range, discard it and obtain a new supply.

Imcivree is given as a subcutaneous injection using a prefilled pen that delivers a fixed 0.5 mg dose. The injection is typically administered into the abdomen, thigh, or upper arm, rotating sites to reduce local irritation. Administration technique and site rotation are explained by the prescribing clinician.

Serious risks include severe injection‑site infections, hypersensitivity reactions such as anaphylaxis, and marked hyperpigmentation that can be disfiguring. Patients should be instructed to report any signs of infection, rash, swelling, or unexpected skin darkening promptly, and clinicians should monitor for these events throughout therapy.

Imcivree is contraindicated in individuals with known hypersensitivity to setmelanotide or any excipients in the formulation. It should also be avoided in patients receiving other MC4R agonists due to the risk of additive effects, and in those where the benefit–risk profile is unfavorable, such as uncontrolled severe infections or unstable cardiovascular disease.